Attention-Deficit/Hyperactivity Disorder as a Risk Factor for COVID-19 Infection

Herman Avner Cohen, Maya Gerstein, Noga Yaniv, Yael Richenberg, Eyal Jacobson, Shoval Marton, Moshe Hoshen, Vered Shkalim Zemer*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review


Objective: To postulate that ADHD is a potential risk factor for COVID-19 infection; to evaluate the COVID-19 risk factor on drug-treated ADHD subjects. Methods: A retrospective chart review was performed on ADHD subjects aged 6 to 18 years in Israel, who had undergone at least one COVID-19 test during the study period. Results: Of the 64,409 subjects included in the study, 6,207 (9.64%) had at least one positive COVID-19 test result, 13,300 (20.65%) were diagnosed with ADHD, and of whom 1,751 (13%) had purchased at least two ADHD medications 3 months prior to COVID-19 testing and were defined as being medically treated. Medically-treated ADHD subjects had a significantly lower likelihood to be infected with COVID-19 than untreated subjects. Conclusion: Untreated ADHD patients seem to constitute a risk group for COVID-19 infection. Drug treatment ameliorates risk of spreading COVID-19 infection within the pediatric population and secondary spread in the general population.

Original languageEnglish
Pages (from-to)985-990
Number of pages6
JournalJournal of Attention Disorders
Issue number7
StatePublished - May 2022


  • ADHD
  • children
  • community healthcare center
  • coronavirus-2019
  • lockdown
  • prevalence
  • psychostimulants


Dive into the research topics of 'Attention-Deficit/Hyperactivity Disorder as a Risk Factor for COVID-19 Infection'. Together they form a unique fingerprint.

Cite this